{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T14:39:44Z","timestamp":1790260784801,"version":"4.1.0"},"reference-count":44,"publisher":"Rockefeller University Press","issue":"7","content-domain":{"domain":["rupress.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,6,30]]},"abstract":"<jats:p>Loss of cell cycle controls is a hallmark of cancer and has a well-established role in aggressive B cell malignancies. However, the role of such lesions in indolent follicular lymphoma (FL) is unclear and individual lesions have been observed with low frequency. By analyzing genomic data from two large cohorts of indolent FLs, we identify a pattern of mutually exclusive (P = 0.003) genomic lesions that impair the retinoblastoma (RB) pathway in nearly 50% of FLs. These alterations include homozygous and heterozygous deletions of the p16\/CDKN2a\/b (7%) and RB1 (12%) loci, and more frequent gains of chromosome 12 that include CDK4 (29%). These aberrations are associated with high-risk disease by the FL prognostic index (FLIPI), and studies in a murine FL model confirm their pathogenic role in indolent FL. Increased CDK4 kinase activity toward RB1 is readily measured in tumor samples and indicates an opportunity for CDK4 inhibition. We find that dual CDK4 and BCL2 inhibitor treatment is safe and effective against available models of FL. In summary, frequent RB pathway lesions in indolent, high-risk FLs indicate an untapped therapeutic opportunity.<\/jats:p>","DOI":"10.1084\/jem.20132120","type":"journal-article","created":{"date-parts":[[2014,6,10]],"date-time":"2014-06-10T07:02:14Z","timestamp":1402383734000},"page":"1379-1391","update-policy":"https:\/\/doi.org\/10.1084\/jem.crossmarkpolicy","source":"Crossref","is-referenced-by-count":34,"title":["Frequent disruption of the RB pathway in indolent follicular lymphoma suggests a new combination therapy"],"prefix":"10.1084","volume":"211","author":[{"given":"Elisa","family":"Oricchio","sequence":"first","affiliation":[{"name":"Cancer Biology & Genetics Program 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Computational Biology Program 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Department of Medicine 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Human Oncology and Pathogenesis Program 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Genomics Core Facility 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Molecular Pharmacology Program 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Department of Pathology 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Department of Epidemiology and Biostatistics 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Cell Biology Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10065 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Ciriello","sequence":"additional","affiliation":[{"name":"Cancer Biology & Genetics Program 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Computational Biology Program 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Department of Medicine 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Human Oncology and Pathogenesis Program 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Genomics Core Facility 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Molecular Pharmacology Program 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Department of Pathology 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Department of Epidemiology and Biostatistics 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Cell Biology Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10065 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Jiang","sequence":"additional","affiliation":[{"name":"Cancer Biology & Genetics Program 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Computational Biology Program 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Department of Medicine 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Human Oncology and Pathogenesis Program 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Genomics Core Facility 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Molecular Pharmacology Program 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Department of Pathology 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Department of Epidemiology and Biostatistics 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Cell Biology Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10065 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Boice","sequence":"additional","affiliation":[{"name":"Cancer Biology & Genetics Program 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Computational Biology Program 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Department of Medicine 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Human Oncology and Pathogenesis Program 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Genomics Core Facility 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Molecular Pharmacology Program 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Department of Pathology 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Department of Epidemiology and Biostatistics 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Cell Biology Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10065 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan H.","family":"Schatz","sequence":"additional","affiliation":[{"name":"Cancer Biology & Genetics Program 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Computational Biology Program 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Department of Medicine 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Human Oncology and Pathogenesis Program 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Genomics Core Facility 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Molecular Pharmacology Program 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Department of Pathology 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Department of Epidemiology and Biostatistics 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Cell Biology Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10065 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Cancer Biology & Genetics Program 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Computational Biology Program 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Department of Medicine 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Human Oncology and Pathogenesis Program 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Genomics Core Facility 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Molecular Pharmacology Program 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Department of Pathology 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Department of Epidemiology and Biostatistics 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Cell Biology Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10065 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Heguy","sequence":"additional","affiliation":[{"name":"Cancer Biology & Genetics Program 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Computational Biology Program 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Department of Medicine 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Human Oncology and Pathogenesis Program 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Genomics Core Facility 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Molecular Pharmacology Program 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Department of Pathology 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Department of Epidemiology and Biostatistics 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Cell Biology Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10065 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes","family":"Viale","sequence":"additional","affiliation":[{"name":"Cancer Biology & Genetics Program 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Computational Biology Program 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Department of Medicine 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Human Oncology and Pathogenesis Program 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Genomics Core Facility 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Molecular Pharmacology Program 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Department of Pathology 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Department of Epidemiology and Biostatistics 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Cell Biology Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10065 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"de Stanchina","sequence":"additional","affiliation":[{"name":"Cancer Biology & Genetics Program 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Computational Biology Program 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Department of Medicine 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Human Oncology and Pathogenesis Program 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Genomics Core Facility 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Molecular Pharmacology Program 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Department of Pathology 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Department of Epidemiology and Biostatistics 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Cell Biology Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10065 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Teruya-Feldstein","sequence":"additional","affiliation":[{"name":"Cancer Biology & Genetics Program 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Computational Biology Program 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Department of Medicine 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Human Oncology and Pathogenesis Program 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Genomics Core Facility 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Molecular Pharmacology Program 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Department of Pathology 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Department of Epidemiology and Biostatistics 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Cell Biology Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10065 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa","family":"Bouska","sequence":"additional","affiliation":[{"name":"Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE 68198 10"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"McKeithan","sequence":"additional","affiliation":[{"name":"Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE 68198 10"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Sander","sequence":"additional","affiliation":[{"name":"Cancer Biology & Genetics Program 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Computational Biology Program 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Department of Medicine 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Human Oncology and Pathogenesis Program 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Genomics Core Facility 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Molecular Pharmacology Program 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Department of Pathology 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Department of Epidemiology and Biostatistics 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Cell Biology Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10065 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne","family":"Tam","sequence":"additional","affiliation":[{"name":"Department of Pathology, Weill-Cornell Medical School, New York, NY 10065 11"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkatraman E.","family":"Seshan","sequence":"additional","affiliation":[{"name":"Cancer Biology & Genetics Program 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Computational Biology Program 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Department of Medicine 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Human Oncology and Pathogenesis Program 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Genomics Core Facility 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Molecular Pharmacology Program 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Department of Pathology 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Department of Epidemiology and Biostatistics 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Cell Biology Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10065 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wing-Chung","family":"Chan","sequence":"additional","affiliation":[{"name":"Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE 68198 10"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.S.K.","family":"Chaganti","sequence":"additional","affiliation":[{"name":"Cancer Biology & Genetics Program 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Computational Biology Program 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Department of Medicine 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Human Oncology and Pathogenesis Program 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Genomics Core Facility 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Molecular Pharmacology Program 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Department of Pathology 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Department of Epidemiology and Biostatistics 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Cell Biology Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10065 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Guido","family":"Wendel","sequence":"additional","affiliation":[{"name":"Cancer Biology & Genetics Program 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Computational Biology Program 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Department of Medicine 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Human Oncology and Pathogenesis Program 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Genomics Core Facility 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Molecular Pharmacology Program 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Department of Pathology 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Department of Epidemiology and Biostatistics 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"},{"name":"Cell Biology Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10065 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , and 9"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"291","published-online":{"date-parts":[[2014,6,9]]},"reference":[{"key":"2023072602181262000_bib1","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/nature11632","article-title":"An integrated map of genetic variation from 1,092 human genomes","volume":"491","author":"1000 Genomes Project Consortium","year":"2012","journal-title":"Nature."},{"key":"2023072602181262000_bib2","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/nature08822","article-title":"The landscape of somatic copy-number alteration across human cancers","volume":"463","author":"Beroukhim","year":"2010","journal-title":"Nature."},{"key":"2023072602181262000_bib3","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1182\/blood-2013-04-496893","article-title":"EZH2 mutations are frequent and represent an early event in follicular lymphoma","volume":"122","author":"B\u00f6d\u00f6r","year":"2013","journal-title":"Blood."},{"key":"2023072602181262000_bib4","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1182\/blood-2013-05-500595","article-title":"Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma","volume":"123","author":"Bouska","year":"2014","journal-title":"Blood."},{"key":"2023072602181262000_bib5","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1101\/gr.125567.111","article-title":"Mutual exclusivity analysis identifies oncogenic network modules","volume":"22","author":"Ciriello","year":"2012","journal-title":"Genome Res."},{"key":"2023072602181262000_bib6","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1182\/blood-2003-07-2469","article-title":"VavP-Bcl2 transgenic mice develop follicular lymphoma preceded by germinal center hyperplasia","volume":"103","author":"Egle","year":"2004","journal-title":"Blood."},{"key":"2023072602181262000_bib7","doi-asserted-by":"crossref","first-page":"4677","DOI":"10.1182\/blood.V91.12.4677","article-title":"Homozygous deletions at chromosome 9p21 involving p16 and p15 are associated with histologic progression in follicle center lymphoma","volume":"91","author":"Elenitoba-Johnson","year":"1998","journal-title":"Blood."},{"key":"2023072602181262000_bib8","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/nchembio817","article-title":"Systems biology and combination therapy in the quest for clinical efficacy","volume":"2","author":"Fitzgerald","year":"2006","journal-title":"Nat. Chem. Biol."},{"key":"2023072602181262000_bib9","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1158\/1078-0432.CCR-11-0509","article-title":"Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4\/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer","volume":"18","author":"Flaherty","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"2023072602181262000_bib10","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1158\/1535-7163.1427.3.11","article-title":"Specific inhibition of cyclin-dependent kinase 4\/6 by PD 0332991 and associated antitumor activity in human tumor xenografts","volume":"3","author":"Fry","year":"2004","journal-title":"Mol. Cancer Ther."},{"key":"2023072602181262000_bib11","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/nrc1299","article-title":"A census of human cancer genes","volume":"4","author":"Futreal","year":"2004","journal-title":"Nat. Rev. Cancer."},{"key":"2023072602181262000_bib12","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1182\/blood-2012-09-457283","article-title":"Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma","volume":"121","author":"Green","year":"2013","journal-title":"Blood."},{"key":"2023072602181262000_bib13","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1038\/sj.leu.2401901","article-title":"Concurrent disruption of p16INK4a and the ARF-p53 pathway predicts poor prognosis in aggressive non-Hodgkin\u2019s lymphoma","volume":"14","author":"Gr\u00f8nbaek","year":"2000","journal-title":"Leukemia."},{"key":"2023072602181262000_bib14","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1182\/blood-2002-07-2298","article-title":"A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival","volume":"101","author":"Hans","year":"2003","journal-title":"Blood."},{"key":"2023072602181262000_bib15","doi-asserted-by":"crossref","first-page":"863","DOI":"10.5858\/2004-128-863-ACEOFL","article-title":"A clinicopathologic evaluation of follicular lymphoma grade 3A versus grade 3B reveals no survival differences","volume":"128","author":"Hsi","year":"2004","journal-title":"Arch. Pathol. Lab. Med."},{"key":"2023072602181262000_bib16","doi-asserted-by":"publisher","first-page":"13520","DOI":"10.1073\/pnas.0804295105","article-title":"Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways","volume":"105","author":"Lenz","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"2023072602181262000_bib17","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1385\/MO:18:1:15","article-title":"Prognostic significance of Ki-67 nuclear proliferative antigen, bcl-2 protein, and p53 expression in follicular and diffuse large B-cell lymphoma","volume":"18","author":"Llanos","year":"2001","journal-title":"Med. Oncol."},{"key":"2023072602181262000_bib18","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1182\/blood.V85.12.3671.bloodjournal85123671","article-title":"Prognostic value of cellular proliferation and histologic grade in follicular lymphoma","volume":"85","author":"Martin","year":"1995","journal-title":"Blood."},{"key":"2023072602181262000_bib19","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.5858\/2007-131-1084-GOFLCO","article-title":"Grading of follicular lymphoma: comparison of routine histology with immunohistochemistry","volume":"131","author":"Martinez","year":"2007","journal-title":"Arch. Pathol. Lab. Med."},{"key":"2023072602181262000_bib20","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/0092-8674(92)90360-O","article-title":"Identification and properties of an atypical catalytic subunit (p34PSK-J3\/cdk4) for mammalian D type G1 cyclins","volume":"71","author":"Matsushime","year":"1992","journal-title":"Cell."},{"key":"2023072602181262000_bib21","doi-asserted-by":"publisher","first-page":"R41","DOI":"10.1186\/gb-2011-12-4-r41","article-title":"GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers","volume":"12","author":"Mermel","year":"2011","journal-title":"Genome Biol."},{"key":"2023072602181262000_bib22","doi-asserted-by":"publisher","first-page":"3228","DOI":"10.1158\/0008-5472.CAN-09-4559","article-title":"Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts","volume":"70","author":"Michaud","year":"2010","journal-title":"Cancer Res."},{"key":"2023072602181262000_bib23","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/ng.518","article-title":"Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin","volume":"42","author":"Morin","year":"2010","journal-title":"Nat. Genet."},{"key":"2023072602181262000_bib24","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nature10351","article-title":"Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma","volume":"476","author":"Morin","year":"2011","journal-title":"Nature."},{"key":"2023072602181262000_bib25","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/nrc3090","article-title":"Cyclin D as a therapeutic target in cancer","volume":"11","author":"Musgrove","year":"2011","journal-title":"Nat. Rev. Cancer."},{"key":"2023072602181262000_bib26","doi-asserted-by":"publisher","first-page":"3769","DOI":"10.1242\/jcs.01210","article-title":"cAMP-induced degradation of cyclin D3 through association with GSK-3\u03b2","volume":"117","author":"Naderi","year":"2004","journal-title":"J. Cell Sci."},{"key":"2023072602181262000_bib27","doi-asserted-by":"crossref","first-page":"6979","DOI":"10.1002\/j.1460-2075.1996.tb01090.x","article-title":"The cell death inhibitor Bcl-2 and its homologues influence control of cell cycle entry","volume":"15","author":"O\u2019Reilly","year":"1996","journal-title":"EMBO J."},{"key":"2023072602181262000_bib28","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/ng.2856","article-title":"Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma","volume":"46","author":"Okosun","year":"2014","journal-title":"Nat. Genet."},{"key":"2023072602181262000_bib29","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1093\/biostatistics\/kxh008","article-title":"Circular binary segmentation for the analysis of array-based DNA copy number data","volume":"5","author":"Olshen","year":"2004","journal-title":"Biostatistics."},{"key":"2023072602181262000_bib30","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/nature03579","article-title":"An inhibitor of Bcl-2 family proteins induces regression of solid tumours","volume":"435","author":"Oltersdorf","year":"2005","journal-title":"Nature."},{"key":"2023072602181262000_bib31","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.cell.2011.09.035","article-title":"The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma","volume":"147","author":"Oricchio","year":"2011","journal-title":"Cell."},{"key":"2023072602181262000_bib32","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1038\/ng.892","article-title":"Analysis of the coding genome of diffuse large B-cell lymphoma","volume":"43","author":"Pasqualucci","year":"2011","journal-title":"Nat. Genet."},{"key":"2023072602181262000_bib33","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.celrep.2013.12.027","article-title":"Genetics of follicular lymphoma transformation","volume":"6","author":"Pasqualucci","year":"2014","journal-title":"Cell Rep."},{"key":"2023072602181262000_bib34","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1038\/ni1245","article-title":"BCL6 interacts with the transcription factor Miz-1 to suppress the cyclin-dependent kinase inhibitor p21 and cell cycle arrest in germinal center B cells","volume":"6","author":"Phan","year":"2005","journal-title":"Nat. Immunol."},{"key":"2023072602181262000_bib35","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1182\/blood.V91.8.2977.2977_2977_2984","article-title":"p16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin\u2019s lymphomas","volume":"91","author":"Pinyol","year":"1998","journal-title":"Blood."},{"key":"2023072602181262000_bib36","doi-asserted-by":"publisher","first-page":"2902","DOI":"10.1200\/JCO.2009.26.1693","article-title":"Prognostic factors in follicular lymphoma","volume":"28","author":"Relander","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"2023072602181262000_bib37","first-page":"365","article-title":"Primer3 on the WWW for general users and for biologist programmers","volume-title":"Bioinformatics Methods and Protocols: Methods in Molecular Biology.","author":"Rozen","year":"2000"},{"key":"2023072602181262000_bib38","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1084\/jem.20110846","article-title":"Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma","volume":"208","author":"Schatz","year":"2011","journal-title":"J. Exp. Med."},{"key":"2023072602181262000_bib39","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1126\/science.274.5293.1672","article-title":"Cancer cell cycles","volume":"274","author":"Sherr","year":"1996","journal-title":"Science."},{"key":"2023072602181262000_bib40","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-C\u00e9ligny","year":"2004","journal-title":"Blood."},{"key":"2023072602181262000_bib41","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1056\/NEJMcibr067155","article-title":"A closer look at follicular lymphoma","volume":"356","author":"Staudt","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"2023072602181262000_bib42","first-page":"1511","article-title":"Bcl-2 has a cell cycle inhibitory function separable from its enhancement of cell survival","volume":"13","author":"Vairo","year":"1996","journal-title":"Oncogene."},{"key":"2023072602181262000_bib43","doi-asserted-by":"publisher","first-page":"4745","DOI":"10.1128\/MCB.20.13.4745-4753.2000","article-title":"Bcl-2 retards cell cycle entry through p27(Kip1), pRB relative p130, and altered E2F regulation","volume":"20","author":"Vairo","year":"2000","journal-title":"Mol. Cell. Biol."},{"key":"2023072602181262000_bib44","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/nature02369","article-title":"Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy","volume":"428","author":"Wendel","year":"2004","journal-title":"Nature."}],"container-title":["Journal of Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/rupress.org\/jem\/article-pdf\/211\/7\/1379\/1750705\/jem_20132120.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/rupress.org\/jem\/article-pdf\/211\/7\/1379\/1750705\/jem_20132120.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T02:18:44Z","timestamp":1690337924000},"score":1,"resource":{"primary":{"URL":"https:\/\/rupress.org\/jem\/article\/211\/7\/1379\/41618\/Frequent-disruption-of-the-RB-pathway-in-indolent"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,9]]},"references-count":44,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,6,30]]}},"URL":"https:\/\/doi.org\/10.1084\/jem.20132120","relation":{},"ISSN":["1540-9538","0022-1007"],"issn-type":[{"value":"1540-9538","type":"electronic"},{"value":"0022-1007","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6,9]]}}}